1
|
Ciraolo E, Althoff S, Ruß J, Rosnev S, Butze M, Pühl M, Frentsch M, Bullinger L, Na IK. Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. Int J Mol Sci 2022; 23:ijms23063207. [PMID: 35328630 PMCID: PMC8955581 DOI: 10.3390/ijms23063207] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 03/11/2022] [Accepted: 03/14/2022] [Indexed: 12/14/2022] Open
Abstract
Immune checkpoint inhibitors (ICI) represented a step forward in improving the outcome of patients with various refractory solid tumors and several therapeutic regimens incorporating ICI have already been approved for a variety of tumor entities. However, besides remarkable long-term responses, checkpoint inhibition can trigger severe immune-related adverse events in some patients. In order to improve safety of ICI as well as T cell therapy, we tested the feasibility of combining T cell-based immunotherapy with genetic disruption of checkpoint molecule expression. Therefore, we generated H-Y and ovalbumin antigen-specific CD8+ T cells with abolished PD-1, LAG-3, and TIM-3 expression through CRISPR/Cas9 technology. CD8+ T cells, subjected to PD-1, LAG-3, and TIM-3 genetic editing, showed a strong reduction in immune checkpoint molecule expression after in vitro activation, while no relevant reduction in responsiveness to in vitro stimulation was observed. At the same time, in B16-OVA tumor model, transferred genetically edited OT-1 CD8+ T cells promoted longer survival compared to control T cells and showed enhanced expansion without associated toxicity. Our study supports the notion that antigen-specific adoptive T cell therapy with concomitant genetic disruption of multiple checkpoint inhibitory receptors could represent an effective antitumor immunotherapy approach with improved tolerability profile.
Collapse
Affiliation(s)
- Elisa Ciraolo
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
| | - Stefanie Althoff
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
| | - Josefine Ruß
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
| | - Stanislav Rosnev
- Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (S.R.); (M.F.)
- Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany
| | - Monique Butze
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
| | - Miriam Pühl
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
| | - Marco Frentsch
- Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (S.R.); (M.F.)
- Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany
| | - Lars Bullinger
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
- Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (S.R.); (M.F.)
- German Cancer Consortium (DKTK), 10117 Berlin, Germany
| | - Il-Kang Na
- Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin, 13125 Berlin, Germany; (E.C.); (S.A.); (J.R.); (M.B.); (M.P.); (L.B.)
- Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany; (S.R.); (M.F.)
- Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany
- German Cancer Consortium (DKTK), 10117 Berlin, Germany
- Correspondence:
| |
Collapse
|